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Background: In response to the global burden of non-communicable diseases (NCDs), the World Health Organization
(WHO) has developed a Global Action Plan that includes a voluntary medicines target of 80% availability and
affordability of essential medicines for the prevention and treatment of diabetes, cardiovascular disease and respiratory
disease both in public and private health facilities. Reliable measures of medicines availability are needed to track
progress towards meeting this target. The results of three studies measuring the availability of medicines for
hypertension and diabetes conducted in Tanzania in 2012–2013 were compared to assess the consistency of the results
across the studies.
Methods: Availability was defined by observation of the medicine (no minimum quantity) on the day of the survey.
The three studies involved 24, 107 and 1297 health facilities. Estimates of the availability of medicines for hypertension
and diabetes were compared for medicines availability overall, by managing authority (government, mission/faith-based,
private-for-profit), by facility level (hospital, health centre, dispensary) and by setting (urban, rural).
Results: Comparisons of the availability of medicines were limited by differences in the definitions of the medicines
and the classifications of the facilities surveyed. Metformin was variously reported as available in 33%, 39%, 46%, and
57% of facilities. Glibenclamide availability ranged from 19% to 52%. One study reported low levels of insulin availability
(9-16% depending on insulin type) compared to 34% in a second study. Captopril (or angiotensin converting enzyme
[ACE] inhibitor) availability ranged from 13% to 48%while availability of calcium channel blockers was 29% to 57% and
beta-blockers 15% to 50%. Trends were similar across studies with lower availability in government compared to
mission or private facilities, in dispensary and health centres compared to hospitals, and in rural compared to
urban facilities.
Conclusions: All three studies showed suboptimal availability of NCD medicines, however the estimates of
availability differed. Regular monitoring using reproducible methods and measuring key medicines must replace
ad-hoc studies, small selected samples and differences in definitions. Low and middle-income countries need to
implement monitoring and evaluation systems to track progress towards meeting the NCD medicines target and
to inform country-level interventions to improve access to NCD medicines.
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Universal access to health care is heavily dependent on
access to affordable essential medicines and health prod-
ucts [1]. Quality-assured essential medicines should be
available at all times in adequate quantities, and at a
price that both individuals and the community can af-
ford [2]. Studies have repeatedly documented the low* Correspondence: Jane.Robertson@newcastle.edu.au
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unless otherwise stated.availability, high prices and poor affordability of key essen-
tial medicines for non-communicable diseases (NCDs) in
many low- and middle-income countries (LMICs) both in
the public and private sectors [3-6].
As the burden of illness in these settings now includes
communicable and NCDs, there is renewed attention on
the poor access to essential medicines for these conditions.
Concern with the high morbidity and mortality associated
with cardiovascular disease, cancer, chronic respiratory
diseases and diabetes is reflected in the United Nationstral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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proving health systems and access to affordable medicines,
particularly at the primary care level, is critical for their
prevention and control [7]. As part of the global response,
the World Health Organization (WHO) has developed a
Global Action Plan and monitoring framework to enable
tracking of progress in preventing and controlling these
major NCDs [8]. The framework includes a voluntary
medicines target of ‘an 80% availability of the affordable
basic technologies and essential medicines, including ge-
nerics, required to treat major non-communicable dis-
eases in both public and private facilities’ [9].
A WHO Package of Essential Noncommunicable (PEN)
disease interventions is designed to integrate the manage-
ment of diabetes, cardiovascular and respiratory disease
into primary health care [10]. The PEN program includes
a list of recommended medicines that should be available
in all primary health care facilities, recognising that al-
though treatment may be initiated at higher levels of the
health care system, patients are likely to use primary
health care facilities for disease management and to access
prescribed medicines. Reviews of facility surveys con-
ducted in LMICs have shown that availability of generic
medicines to treat NCDs is lower than for communicable
diseases in both the public (36.0% vs. 53.5%) and private
sectors (54.7% vs. 66.2%) [3].
Measuring progress towards achieving the 80% medi-
cines target requires regular measurement of the availabil-
ity of key NCD medicines, although there is currently no
standardized methodology recommended by WHO for
doing this. Few LMICs have country-level surveillance
and monitoring systems in place to be able to chart pro-
gress, relying instead on ad-hoc studies and surveys to fill
these information gaps. The reliability and representative-
ness of these ad-hoc survey data are often assumed. How-
ever, if availability estimates from the studies are similar,
this would lend support to using the simplest, most effi-
cient method of data collection in settings where routine
data collection and monitoring systems are not yet in
place. Tanzania was the only example we found where
there was more than one study using different methods
and with sufficient data on the availability of NCD medi-
cines to allow meaningful comparisons. Data from three
studies conducted in Tanzania in 2012–2013 [11-13] pro-
viding estimates of the availability of key essential medi-
cines used to treat hypertension and diabetes allowed us
to examine the consistency of the results across the stud-
ies and to compare the resulting inferences on access to
essential medicines for these NCDs.
Methods
Point-in-time estimates of the availability of medicines,
based on the observation of the study medicines on theday of the visit regardless of the quantity of stock present,
were extracted from each of the three studies.
Peck et al. assessed health facility preparedness for
the outpatient treatment of hypertension and diabetes
in Tanzania [11]. The assessment, conducted between
November 2012 and May 2013, involved 24 public or
private not-for-profit health facilities in the selected
study areas, including four hospitals (two referral and
two district hospitals), eight health centres (two urban
and six rural) and 12 dispensaries (six urban and six
rural). Purposive sampling was used to select hospitals
for the study while other facilities were randomly se-
lected. Medicines included in this study were metformin
and short-acting, intermediate-acting, and long-acting
insulins for the treatment of diabetes, and atenolol or pro-
pranolol, captopril or lisinopril, nifedipine, and hydro-
chlorothiazide or bendrofluazide for the management
of hypertension.
A study using the World Health Organization-Health
Action International (WHO-HAI) survey methodology
was conducted in Tanzania in September 2012 [12]. The
107 health facilities surveyed included 37 Government
(public) facilities, 34 Mission (Faith-based organization)
facilities and 36 private-for-profit facilities (licensed
pharmacies and drug stores). For each of the study sur-
vey areas, a minimum of five public sector outlets were
chosen including the main public hospital and four
medicine outlets (primary health care centres or district
hospitals). Private-for-profit and mission medicine out-
lets are the closest facility of that type to the selected
public sector facility. As a medicines prices and availabil-
ity survey, the WHO-HAI study specifies the form and
strength of the medicine surveyed. Relevant for this
study were the following medicines: glibenclamide 5 mg
and metformin 500 mg tablets for diabetes and atenolol
50 mg, captopril 25 mg and nifedipine retard 20 mg tab-
lets for hypertension.
The third study was a World Health Organization
Service Availability and Readiness Assessment (SARA)
[13,14]. The assessment of service readiness reflects the
ability of the facility to provide general and specific ser-
vices at minimum standards and includes the availabil-
ity of key medicines and health commodities. The
sample of facilities is drawn from a master list of all
public, private non-profit, private for-profit and faith-
based health facilities, including hospitals, health cen-
tres, dispensaries and specialized clinics in the country.
The SARA was conducted in 27 districts in Tanzania with
a final sample of 1297 facilities, representing more than
18% of all health facilities in Tanzania and stratified by
facility level (dispensary, health centre, hospital), managing
authority Government/public, Mission or Faith-based
organization, not-for-profit NGO, private-for-profit), own-
ership (Government/public, private) and residence (urban
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service assessments of all 1297 health facilities surveyed
(specific tracer medicines: glibenclamide 5 mg, atenolol
50 mg, captopril 25 mg tablets) and from facilities
meeting standards for providing diabetes services (248
facilities: glibenclamide, metformin, insulin) and car-
diovascular services (316 facilities: beta-blockers, ACE
inhibitors, calcium channel blockers, thiazide diuretics).
In order to compare the results from the different de-
signs, the analyses presented show the mean availability
(%) for the medicines across the facilities surveyed and
as reported in each of the three studies. Data were ex-
tracted by two authors working independently with dis-
crepancies managed by discussion and consensus. In
addition, where possible, data were re-analysed using the
raw data to allow comparisons of medicines availability
overall and by facility setting that were not presented in
the original publications. To examine distributional ef-
fects, the mean availability of metformin and ACE in-
hibitors (recommended first line treatments in PEN
guidelines for diabetes and hypertension respectively) is
summarised by managing authority (government, mis-
sion or faith-based organization, private-for-profit), by
facility level (hospital, health centre, dispensary) and by
setting (urban, rural).Table 1 Availability of medicines for diabetes and hypertensi
Medicine Mean availability (%) of medic
Peck et al. WHO/HAI S
A




Insulin 17; 8; 8‡
Hypertension
Captopril 25 mg 48 1




Atenolol 50 mg 48 1
Atenolol or propranolol 50
Beta-blockers
Hydrochlorothiazide or bendrofluazide 33
FBO = Faith Based Organization; SR = sustained release formulation.
#Availability of essential tracer medicines is measured across all health facilities surv
*glibenclamide 5 mg tablet.
†metformin 500 mg tablet.
‡short-acting, intermediate-acting and long-acting insulin assessed separately.
§WHO/HAI survey specified 20 mg sustained-release formulation.
¥specified as thiazide diuretics.Ethics approval was not required for this study that
uses aggregate data from publicly available data sources.Results
The differences in the level of specification of the medi-
cines included in the three studies and the classification
of the health facilities surveyed affected the comparisons
on medicines availability that could be made (Table 1).Diabetes medicines
Glibenclamide availability ranged from 19% (5 mg tablet,
all facilities SARA survey) to 52% (no strength specified,
SARA diabetes services). Metformin 500 mg was avail-
able in 46% of facilities in the WHO-HAI survey, met-
formin availability (no strength specified) ranged from
33% (Peck et al.) to 57% (SARA diabetes services). Met-
formin was also reported available in 39% of facilities
providing cardiovascular services (SARA). Peck et al.
reported low levels of availability of insulin (8-17% de-
pending on insulin type) while at least one type of insu-
lin was available in 34% of facilities providing diabetes
services (SARA). Insulin availability was not examined
in the WHO-HAI survey.on
ine
ARA
ll facilities# Diabetes services Cardiovascular disease services
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The reported availability of captopril 25 mg tablets
ranged from 13% (SARA all facilities) to 48% (WHO-
HAI survey). There was only 24% availability reported
for the broader category ‘ACE inhibitors’ in facilities pro-
viding cardiovascular services (SARA). Availability of
calcium channel blockers ranged from 29% (no specified
medicine SARA cardiovascular services) to 57% (nifedi-
pine SR 20 mg WHO-HAI survey). Availability of ateno-
lol 50 mg tablets was reported in 48% of facilities in the
WHO-HAI survey however in only 15% of all facilities
in the SARA. Peck et al. reported 50% availability of
atenolol or propranolol in the 24 facilities surveyed. Esti-
mates of the availability for thiazide diuretics were simi-
lar in SARA cardiovascular services (31%) and the Peck
et al. study (33%).
Analyses by managing authority, facility level and setting
Availability of metformin was lower in government
compared to mission or private facilities in both the
WHO-HAI survey and the SARA, although the numeric
estimates differed considerably between the studies (30%,
65%, 44% compared to 42%, 93%, 82%, Table 2). Likewise,
there was a consistent pattern of greater availability of
metformin in hospital than in health centre and dispensary
settings, and in urban compared to rural settings. How-
ever, there were substantial differences in these estimates
between the Peck et al. and SARA diabetes services es-
timates (Table 2). Notably, Peck et al. reported no avail-
ability of metformin in rural facilities surveyed while
availability was 42% in the SARA.Table 2 Availability of metformin by facility type and
setting
Medicine Observed mean availability (%) of medicine





N = 24 N = 107 N = 248
Metformin* Metformin 500 mg Metformin
Metformin




Private facility 44 82
Hospital 100 87




*Metformin 500 mg is listed in 2013 Tanzania National Essential Medicines List.Similar patterns of availability applied to ACE inhibi-
tors, notwithstanding the differences in level of specifica-
tion of the medicines in each study (Table 3). As with
metformin, there were notable differences in the esti-
mates of availability between studies.
Discussion
The three studies were conducted in a similar time period
yet provide substantially different estimates of the avail-
ability of medicines for the treatment of diabetes and
hypertension in Tanzania.
The overall conclusions of each of the three studies
are consistent, i.e. that availability of key NCD medicines
for the management of diabetes and hypertension is sub-
optimal. In addition, there were consistent patterns of
lower availability in government facilities than mission/
faith-based and private facilities with lower availability in
dispensaries and health centres than in hospitals and
lower availability in rural than urban health facilities.
These differences will impact on the ability to provide
equitable access to diabetes and hypertension treatments
for patients. However estimating the extent of these
problems is difficult given the ranges of estimates in the
three studies.
The abstract of the Peck et al. study states that “a repre-
sentative sample of 24 public and not-for-profit health
facilities in urban and rural Tanzania” was used. These au-
thors refer to the use of an adapted version of the WHO
SARA questionnaire to assess facility readiness to provide
chronic disease services. However the sample size used is
much smaller than that used in a nationally representativeTable 3 Availability of ACE inhibitors by facility type and
setting
Medicine Observed mean availability (%) of medicine
Peck et al. WHO/HAI
survey
SARA
N = 24 N = 107 Cardiovascular

















*Captopril and perindopril listed in 2013 Tanzania National Essential Medicines List.
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mates of medicines availability (and prices). However it
uses purposive rather than representative sampling, aim-
ing to strike a balance between representativeness and
practicality [15]. The limited stratification of health facil-
ities in WHO-HAI surveys will limit the usefulness of the
data for sector planning within countries.
SARAs are carried out at the request of Ministries of
Health in advance of planned country health policy re-
views in order to inform health decision-making. Sam-
pling methods used depend on country application. A
nationally representative random sample of at least 150
health facilities can be used to obtain national esti-
mates, while a district-level assessment with a census
of all facilities in selected districts can generate results
that can be used for local management [14]. The SARA
for Tanzania included more than 18% of all health fa-
cilities in Tanzania, and will therefore most closely re-
flect the situation of medicines availability in the
country. With analyses stratified by facility type, oper-
ating authority, ownership and residence (urban and
rural areas) a more detailed understanding of within-
country problems of medicines availability is possible,
allowing targeted interventions to address procurement
and distribution issues. However a SARA is a resource
intensive data collection exercise and to date, these
have mostly been conducted in Africa with the support
of donors.
The availability and affordability of medicines are
central to health service delivery in any community.
When medicines are not available in the public sector
people go elsewhere for their health care, often forced
into the private sector where medicines are more avail-
able but also more expensive, indeed unaffordable for
some. Increasing access to essential, quality-assured,
safe, effective and affordable medical products is one
of the global leadership priorities for WHO [16]. The
results presented here relate to medicines availability,
only the WHO-HAI study also assessed medicines
prices.
As the disease burden in LMICs shifts from commu-
nicable to NCDs, the issue of the availability and af-
fordability of critical NCD medicines becomes more
important. NCDs represent a paradigm shift in the way
health systems are organized and in treatment ap-
proaches as patients need to understand that treatment
does not stop once they feel better and that life-long
therapy is required for sometimes asymptomatic condi-
tions like hypertension and hyperlipidaemia. No medi-
cines or interrupted medicines supplies in public
facilities, difficulties in accessing medicines from other
sources and higher than necessary costs in the private
sector will compromise the adherence to treatment
needed to achieve the desired clinical outcomes.The results presented here suggest problems with avail-
ability of NCD medicines, particularly in the public sector
and rural areas, leading to low availability of NCD medi-
cines that are themselves relatively cheap. Medicines like
metformin, glibenclamide and ACE inhibitors are long out
of patent, and there are multi-source products. Availability
and affordability of insulin is a well-recognised problem in
low and middle-income countries, with the additional
costs of syringes and other diabetes commodities adding
to the treatment burden [17].
None of the three studies explored reasons for the low
availability of medicines reported. The estimates should
stimulate further enquiry as to why the medicines are not
available. For example, lower availability in the public sec-
tor across all facility types and locations compared to the
private sector could reflect inadequate government funds
to purchase sufficient medicines to meet patient needs. If
availability in the public sector is consistently lower in
rural areas, it could suggest problems with procurement
and distribution systems to the more distant health facil-
ities. Paradoxically, medicines being available could mean
that the medicines are not being prescribed by the health
care providers in that district (i.e. low demand). Different
types of follow-up enquiry are required in each case to de-
termine the causes of the poor availability.
These availability surveys provide no information on
the diagnosis and management of hypertension and dia-
betes or the treatment choices of health care profes-
sionals. Recent estimates suggest that many individuals
with hypertension in Africa are unaware of their condi-
tion [18]. In addition, hypertension may rank low as a
health priority competing with treatments for infectious
diseases for limited resources [19]. Low demand may
also explain in part the relatively low availability in the
private sector reported here.
With the global focus on improvements in access and
affordability of NCD medicines, it is essential to have a
reliable platform for measuring supply system weak-
nesses and assessing changes in medicines availability. A
fragmented approach to measurement relying on ad-hoc
studies leads to information gaps and duplication of ef-
forts while limiting the ability to monitor trends over
time. Preferable is systematic monitoring of medicines
availability and prices that can help identify potential
problems and the corrective actions required and a cul-
ture of using data to inform decision-making and plan-
ning at the country level. LMICs will require support to
develop these monitoring systems.
The World Health Assembly (WHA) 2013 focused
on the linkages of NCDs to Universal Health Coverage
(UHC) and the role of essential medicines in improving
patient access to affordable medicines [20]. The meas-
urement of NCD medicines availability is not only rele-
vant to assessing the 80% medicines availability target
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achievement of UHC. This monitoring should be built
into public health programs at the national, regional,
and service delivery level and requires routine collec-
tion of good quality data that are valid and reliable,
using standardised and reproducible methods. Methods
for data collection ideally should be simple, focus on a
smaller number of key medicines, and be able to be under-
taken on a regular basis, preferably without substantial
additional costs to the health services. Monitoring, evalu-
ation and review of data with a view to corrective actions
should be part of the national health strategy.
Conclusions
Given the differences between study estimates, none of
the three methods completely meets the needs for moni-
toring availability of NCD medicines at a country level.
The challenge is establishing a meaningful platform from
which to judge the effects of efforts to improve access to
medicines. There is an urgent need for a different ap-
proach that moves beyond ad-hoc studies and focuses
on reliable and reproducible information to support
decision-making. Countries need to build this into their
routine information systems. Along with this, there must
be a culture of using information to investigate problems
and propose concrete solutions to improve access to es-
sential medicines.
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